Procept Biorobotics (PRCT) closed at $20.62 on November 6, 2026, up 1.7% from the previous close, on volume of 1,571,676 shares (30-day average 1,309,993).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Strangle or Risk Reversal | 20-Nov-2617.5 P : 25 C | 4,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
PROCEPT’s New Prostate Cancer Trial Puts Aquablation Against Active Surveillance
TipRanks (Fri, 6-Nov 11:31 AM ET)
PROCEPT BioRobotics (PRCT) Gets a Hold from Oppenheimer
TipRanks (Thu, 5-Nov 10:16 PM ET)
TipRanks (Thu, 5-Nov 6:00 PM ET)
TipRanks (Thu, 5-Nov 9:20 AM ET)
PROCEPT BioRobotics (PRCT) Gets a Buy from TD Cowen
TipRanks (Thu, 5-Nov 9:07 AM ET)
At a glance: stocks gapping down premarket
Seeking Alpha News (Thu, 5-Nov 7:34 AM ET)
Piper Sandler Sticks to Their Buy Rating for PROCEPT BioRobotics (PRCT)
TipRanks (Thu, 5-Nov 7:29 AM ET)
BTIG Sticks to Its Hold Rating for PROCEPT BioRobotics (PRCT)
TipRanks (Thu, 5-Nov 6:15 AM ET)
TipRanks (Thu, 5-Nov 3:41 AM ET)
Procept GAAP EPS of -$0.46 misses by $0.07, revenue of $98.3M misses by $2.22M
Seeking Alpha News (Wed, 4-Nov 4:23 PM ET)
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Procept Biorobotics trades on the NASDAQ stock market under the symbol PRCT.
As of November 6, 2026, PRCT stock price climbed to $20.62 with 1,571,676 million shares trading.
PRCT has a beta of 0.24, meaning it tends to be less sensitive to market movements. PRCT has a correlation of 0.00 to the broad based SPY ETF.
PRCT has a market cap of $1.18 billion. This is considered a Small Cap stock.
Last quarter Procept Biorobotics reported $98 million in Revenue and -$.46 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.07.
In the last 3 years, PRCT traded as high as $103.81 and as low as $16.67.
The top ETF exchange traded funds that PRCT belongs to (by Net Assets): VTI, IWM, VB, VBK, VXF.
PRCT has underperformed the market in the last year with a return of -34.1%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PRCT shares. However, PRCT has outperformed the market in the last 3 month and 2 week periods, returning +2.9% and +3.3%, while SPY returned -4.1% and -3.2%, respectively. This indicates PRCT has been having a stronger performance recently.
PRCT support price is $19.28 and resistance is $21.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRCT shares will trade within this expected range on the day.
